Publications (Selected)
2023
Zhou J, Wang H, Shu T, Wang J, Yang W, Li J, Ding L, Liu M, Sun H, Wong J, Lai PB, Tsang SW, Ward SE, Chow KL, Sung JJ, Sze-Lok Cheng A. Myeloid-intrinsic cell cycle-related kinase drives immunosuppression to promote tumorigenesis. iScience. 2023 Aug 12. http://doi.org/10.1016/j.isci.2023.107626
Chen J, Chan TTH, Zhou J#. Lipid Metabolism in the Immune Niche of Tumor-Prone Liver Microenvironment. J Leukoc Biol. 2023 July 20;qiad081. https://doi.org/10.1093/jleuko/qiad081
Xiong Z, Chan SL, Zhou J*, Vong JSL, Kwong TT, Zeng X, Wu H, Cao J, Tu Y, Feng Y, Yang W, Wong PP, Si-Tou WW, Liu X, Wang J, Tang W, Liang Z, Lu J, Li KM, Low JT, Chan MW, Leung HHW, Chan AWH, To KF, Yip KY, Lo YMD, Sung JJ, Cheng AS. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma. Gut. 2023 Apr 5:gutjnl-2022-328364. https://doi.org/10.1136/gutjnl-2022-328364
2022
Tan Z, Chiu MS, Yang X, Yue M, Cheung TT, Zhou D, Wang Y, Chan AW, Yan CW, Kwan KY, Wong YC, Li X, Zhou J, To KF, Zhu J, Lo CM, Cheng AS, Chan SL, Liu L, Song YQ, Man K, Chen Z. Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients. Gut. 2022 Nov 30. gutjnl-2022-327133. https://doi.org/10.1136/gutjnl-2022-327133
Liu X, Zhou J, Wu H, Chen S, Zhang L, Tang W, Duan L, Wang Y, McCabe E, Hu M, Yu Z, Liu H, Choi C, Sung JJY, Huang L, Liu R, Cheng AS. Fibrotic immune microenvironment remodeling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma. Mol Ther. 2022 Sep 22;S1525-0016(22)00566-4. https://doi.org/10.1016/j.ymthe.2022.09.012
Tang W, Zhou J#, Yang W, Feng Y, Wu H, Mok MTS, Zhang L, Liang Z, Liu X, Xiong Z, Zeng Z, Wang J, Lu J, Li J, Sun H, Tian X, Yeung PC, Hou Y, Lee HM, Lam CCH, Leung HHW, Chan AWH, To KF, Wong J, Lai PBS, Ng KKC, Wong SKH, Wong VWS, Kong APS, Sung JJY, Cheng AS#. Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver. Cell Mol Immunol. 2022 May 20; 834–847. https://doi.org/10.1038/s41423-022-00872-3
2021
Wong W, Yin B, Rakhmatullina A, Zhou J#, Wong SH#. Engineering advanced dynamic biomaterials to optimize adoptive T-cell immunotherapy. Engineered Reg. 2021 Jun. https://doi.org/10.1016/j.engreg.2021.06.001
Zeng X, Ward Simon E, Zhou J#, Cheng AS#. Liver immune microenvironment and metastasis from colorectal cancer-pathogenesis and therapeutic perspectives. Cancers. 2021 May 17;13(10):2418. https://doi.org/10.3390/cancers13102418
Zeng X, Zhou J#, Xiong Z, Sun H, Yang W, Mok M, Wang J, Li J, Liu M, Tang W, Feng Y, Wang HKS, Tsang SW, Chow KL, Yeung C, Wong J, Lai PBS, Chan AWH, To KF, Chan SL, Xia Q, Xue J, Chen X, Yu J, Peng S, Sung JJY, Kuang M, Cheng AS#. Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis. Cell Mol Immunol. 2021 Apr;18(4):1005-1015. https://doi.org/10.1038/s41423-020-00534-2
Yang W*, Feng Y*, Zhou J*, Cheung OK, Cao JQ, Wang J, Tang WS, Tu YL, Xu LL, Wu F, Tan Z, Sun H, Tian Y, Wong J, Lai PB, Chan SL, Chan AW, Tan P, Chen Z, Sung JJ, Yip KYL, To KF, Cheng AS. Enhancer reprogramming by selective HDAC8 inhibition potentiates T cell infiltration and durable antitumor efficacy of PD-L1 blockade. Sci Transl Med. 2021 Apr 7;13(588). https://doi.org/10.1126/scitranslmed.aaz6804
Kwong TT, Wong CH, Zhou J, Cheng AS, Sung JJ, Chan AW, Chan SL. Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade. JHEP Rep. 2021 Apr 1; 3 (2), 100224. https://doi.org/10.1016/j.jhepr.2020.100224
2018-2020
Liu M*, Zhou J*, Liu X, Feng Y, Yang W; Wu F; Cheung OKW; Sun H; Zeng X; Tang W; Mok M; Wong J; Yeung PC; Lai PBS; Jin H; Chen J; Chan SL; Chan AWH; To KF; Chen Z; Sung JJ; Chen M; Cheng AS. Targeting Monocyte-intrinsic Enhancer Reprogramming Improves Immunotherapy Efficacy in Hepatocellular Carcinoma. Gut. 2020 Feb; 69(2):365-379. https://doi.org/10.1136/gutjnl-2018-317257
Sun H, Yang W, Tian Y, Zeng X, Zhou J, Mok MTS, Tang W, Feng Y, Xu L, Chan AWH, Tong JH, Cheung YS, Lai PBS, Wang HKS., Tsang SW, Chow KL, Hu M, Liu R, Huang L, Yang B, Yang P, To KF, Sung JJ, Wong GLH, Wong VWS, Cheng AS. An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma. Nat Commun. 2018 Dec; 6;9(1):5214. https://doi.org/10.1038/s41467-018-07402-8
Tang J, Cai Y, Liang J, Tan Z, Tang X, Zhang C, Cheng L, Zhou J, Wang H, Yam WC, Chen X, Wang H, Chen Z. In vivo electroporation of a codon-optimized BER(opt) DNA vaccine protects mice from pathogenic Mycobacterium tuberculosis aerosol challenge. Tuberculosis. 2018. Dec; 113: 65-75. https://doi.org/10.1016/j.tube.2018.07.003
Zhou J, Liu M, Sun H, Feng Y, Xu L, Chan AWH, Tong JH, Wong J, Chong CCN, Lai PBS, Wang HK, Tsang SW, Goodwin T, Liu R, Huang L, Chen Z, Sung JJ, Chow KL, To KF, Cheng AS. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut. 2018 May; 67:931-944. https://doi.org/10.1136/gutjnl-2017-314032
Mok M, Zhou J, Tang W, Zeng X, Oliver AW, Ward SE, Cheng AS. CCRK is a novel signalling hub exploitable in cancer immunotherapy. Pharmacol Ther. 2018 Mar; 186:138-151. https://doi.org/10.1016/j.pharmthera.2018.01.008
# Publications as corresponding/co-corresponding author
* Publications as first/co-first author